ENDV Financials Monday, July 14, 2014 11:13:03 PM

ENDV Financials Monday, July 14, 2014 11:13:03 PM
Endonovo Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 23 - 46 51
Cost of Revenue 14 - - -
Gross Profit 9 - 46 51
Operating Expenses
Research and Development - - - -
Sales, General and Admin. - - 137 115
Non-Recurring Items - - 3 13
Other - - 1 1
Operating Income (2,429) (1,737) (96) (78)
Income From Continuing Operations
Add'l Income/Expense Items (196) (59) 2 9
Earnings Before Interest and Tax (2,625) (1,796) (93) (69)
Interest Expense 268 114 - -
Earnings Before Tax (2,892) (1,909) (93) (69)
Income Tax 1 - 1 1
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (2,893) (1,909) (94) (69)
Non Recurring Events
Discontinued Operations - (5) - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (2,893) (1,915) (94) (69)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (2,893) (1,915) (94) (69)